In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Baxter announces plans to spin off biopharma operations as Baxalta

Executive Summary

Baxter International Inc., which announced in March its intention to split into two publicly traded companies--one focused on biopharmaceuticals, the other on medical products--in a tax-free distribution to shareholders, revealed it plans to spin off the Baxter BioScience biopharma operations as Baxalta Inc., a publicly traded company that will list on the NYSE under the symbol BXLT.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Acquisition
    • Divestiture/Spin-Out

Related Companies